Literature DB >> 11874386

Sex and age differences in the pharmacokinetics of alosetron.

K M Koch1, J L Palmer, N Noordin, J J Tomlinson, C Baidoo.   

Abstract

AIMS: To determine the effects of sex and age on the pharmacokinetics of alosetron.
METHODS: Single oral and intravenous 2 mg doses of alosetron were administered on separate occasions to 48 healthy, young and elderly, males and females. Serum was sampled for 12 h post-dose to measure alosetron concentrations.
RESULTS: Serum concentrations of alosetron were higher in females than in males, resulting from a sex difference in clearance by metabolism. Mean clearance values were 504 vs 677 ml min(-1) in young females vs males (mean ratio 0.75), and 461 vs 670 ml min(-1) in elderly females vs males (mean ratio 0.69). The sex difference in alosetron pharmacokinetics achieved statistical significance in the elderly, but not in the young. Irrespective of sex, alosetron clearance was increased by smoking. Serum concentrations tended to be higher in the elderly, although the effect of age was generally not significant. Volume of distribution was smaller in females (approximately 63 l) compared with males (approximately 84 l), regardless of age or the sex difference in body weight.
CONCLUSIONS: A significant difference in clearance by metabolism of alosetron between the sexes, and possibly between the young and elderly was observed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11874386      PMCID: PMC1874312          DOI: 10.1046/j.0306-5251.2001.01565.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  Influence of patient-related variables on clozapine plasma levels.

Authors:  C Haring; W W Fleischhacker; P Schett; C Humpel; C Barnas; A Saria
Journal:  Am J Psychiatry       Date:  1990-11       Impact factor: 18.112

2.  Effect of age and gender on the activity of human hepatic CYP3A.

Authors:  C M Hunt; W R Westerkam; G M Stave
Journal:  Biochem Pharmacol       Date:  1992-07-22       Impact factor: 5.858

3.  Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients.

Authors:  P B Watkins; S A Murray; L G Winkelman; D M Heuman; S A Wrighton; P S Guzelian
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

4.  Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.

Authors:  M Camilleri; A R Northcutt; S Kong; G E Dukes; D McSorley; A W Mangel
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

Review 5.  Olanzapine. Pharmacokinetic and pharmacodynamic profile.

Authors:  J T Callaghan; R F Bergstrom; L R Ptak; C M Beasley
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

6.  Epidemiology of irritable bowel syndrome in the United States.

Authors:  R S Sandler
Journal:  Gastroenterology       Date:  1990-08       Impact factor: 22.682

7.  Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables.

Authors:  L Ereshefsky; S R Saklad; M D Watanabe; C M Davis; M W Jann
Journal:  J Clin Psychopharmacol       Date:  1991-10       Impact factor: 3.153

8.  Clinical implications of the pharmacology of sertraline.

Authors:  S J Warrington
Journal:  Int Clin Psychopharmacol       Date:  1991-12       Impact factor: 1.659

9.  Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities.

Authors:  M V Relling; J S Lin; G D Ayers; W E Evans
Journal:  Clin Pharmacol Ther       Date:  1992-12       Impact factor: 6.875

10.  Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer's disease.

Authors:  J M Ford; C A Truman; G K Wilcock; C J Roberts
Journal:  Clin Pharmacol Ther       Date:  1993-06       Impact factor: 6.875

View more
  15 in total

1.  The effect of fluvoxamine on the pharmacokinetics, safety, and tolerability of ramosetron in healthy subjects.

Authors:  Takeshi Kadokura; Martin den Adel; Walter J J Krauwinkel; Tetsuo Takeshige; Akito Nishida
Journal:  Eur J Clin Pharmacol       Date:  2008-04-26       Impact factor: 2.953

Review 2.  The role of gender and biological sex in irritable bowel syndrome.

Authors:  Christine L Frissora; Kenneth L Koch
Journal:  Curr Gastroenterol Rep       Date:  2005-08

Review 3.  The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D).

Authors:  Yang Won Min; Poong-Lyul Rhee
Journal:  Therap Adv Gastroenterol       Date:  2015-05       Impact factor: 4.409

4.  Sex difference in irritable bowel syndrome: do gonadal hormones play a role?

Authors:  Agata Mulak; Yvette Taché
Journal:  Gastroenterol Pol       Date:  2010

Review 5.  Do fluctuations in ovarian hormones affect gastrointestinal symptoms in women with irritable bowel syndrome?

Authors:  Margaret M Heitkemper; Lin Chang
Journal:  Gend Med       Date:  2009

Review 6.  Rational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions.

Authors:  Quan Zhou; Xiao-Feng Yan; Zhong-Miao Zhang; Wen-Sheng Pan; Su Zeng
Journal:  World J Gastroenterol       Date:  2007-11-14       Impact factor: 5.742

7.  Identification of patients with non-d, non-C irritable bowel syndrome and treatment with renzapride: an exploratory, multicenter, randomized, double-blind, placebo-controlled clinical trial.

Authors:  R C Spiller; N L Meyers; R I Hickling
Journal:  Dig Dis Sci       Date:  2008-05-10       Impact factor: 3.199

Review 8.  Sex hormones in the modulation of irritable bowel syndrome.

Authors:  Agata Mulak; Yvette Taché; Muriel Larauche
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

9.  Population pharmacokinetics of ramosetron.

Authors:  Seong Heon Lee; Soo Young Cho; Kyung Yeon Yoo; Seongwook Jeong
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-11-11       Impact factor: 2.745

Review 10.  Sex-Bias in Irritable Bowel Syndrome: Linking Steroids to the Gut-Brain Axis.

Authors:  Sik Yu So; Tor C Savidge
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-19       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.